ReviewThe AAPS journal2015
Strategic approaches to optimizing peptide ADME properties.
Review in The AAPS journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 280 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
280 citing papers in PubMed.
- Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia.Clinical pharmacokinetics · 2022Trial
- Virtual screening and experimental validation of a METTL3-targeting peptide withJournal of enzyme inhibition and medicinal chemistry · 2026Article
- Minimalist d‑Tripeptide Prodrug Mimetics of the Myostatin Prodomain as Selective Inhibitors of Skeletal Muscle Atrophy Signaling.ACS medicinal chemistry letters · 2026Article
- Chicken cathelicidin-3 protected mice from avian pathogenic Escherichia coli infection mediated by triggering chemokine CCL3 pathway.Veterinary research · 2026Article
- Peptidomics-guided 3D structural-mechanistic investigation of bovine colostrum peptides reveals multi-targetedFood chemistry: X · 2026Article
- The Effect of Protecting Groups and Peptide Chain Length on the Aqueous Solubility of l‑Alanine Homopeptides.ACS omega · 2026Article
- Bioactive Peptides from Andean Crops: Lactic Acid Bacteria Fermentation, Complementary Proteolysis, and Biological Activities.Foods (Basel, Switzerland) · 2026Review
- Advances in Cyclic Peptides Targeting G Protein-Coupled Receptors.Chembiochem : a European journal of chemical biology · 2026Review
- In silico identification of selective cyclodecapeptide inhibitors targeting Plasmodium falciparum Grp78 chaperone.Journal of computer-aided molecular design · 2026Article
- Peptides as programmable molecular scaffolds: from chemical synthesis and engineering to translational medicine.RSC chemical biology · 2026Review
- Article
- Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets.Pharmaceutics · 2026Article
- Exploring the antibacterial potential of a designed peptide against Gardnerella vaginalis.Molecular biology reports · 2026Article
- BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.Pharmaceutics · 2026Review
- Predicting enzymatic cleavage sites in cyclic peptides with non-canonical amino acids using a Graphormer model trained on MetID user data.Scientific reports · 2026Article
- Reversible, Polymeric Complexation of Therapeutic Peptides Using Esterification.ACS macro letters · 2026Article
- Self-Assembling Short Peptide Carriers for Gene Delivery.International journal of molecular sciences · 2026Review
- Development of Cathepsin B‑Activatable Cell-Penetrating Peptides for Tumor Targeting.ACS pharmacology & translational science · 2026Article
- Systemic Pharmacokinetic Principles of Therapeutic Peptides.Clinical pharmacokinetics · 2026Article
- The Biggest Challenge for Prediction of Membrane Permeability of Cyclic Peptides: Scarce Data Availability.Journal of medicinal chemistry · 2026Article
220 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Development of peptide drugs is challenging but also quite rewarding. Five blockbuster peptide drugs are currently on the market, and six new peptides received first marketing approval as new molecular entities in 2012. Although peptides only represent 2% of the drug market, the market is growing twice as quickly and might soon occupy a larger niche. Natural peptides typically have poor absorption, distribution, metabolism, and excretion (ADME) properties with rapid clearance, short half-life, low permeability, and sometimes low solubility. Strategies have been developed to improve peptide drugability through enhancing permeability, reducing proteolysis and renal clearance, and prolonging half-life. In vivo, in vitro, and in silico tools are available to evaluate ADME properties of peptides, and structural modification strategies are in place to improve peptide developability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.